Principal Financial Group Inc. Purchases 14,480 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Principal Financial Group Inc. lifted its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 28.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 66,060 shares of the medical instruments supplier’s stock after acquiring an additional 14,480 shares during the quarter. Principal Financial Group Inc. owned 0.09% of OraSure Technologies worth $282,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Ballentine Partners LLC bought a new stake in shares of OraSure Technologies in the 3rd quarter worth approximately $159,000. Assenagon Asset Management S.A. raised its stake in shares of OraSure Technologies by 25.7% in the third quarter. Assenagon Asset Management S.A. now owns 205,559 shares of the medical instruments supplier’s stock valued at $878,000 after buying an additional 42,017 shares during the period. Koss Olinger Consulting LLC lifted its position in shares of OraSure Technologies by 9.4% during the 3rd quarter. Koss Olinger Consulting LLC now owns 83,977 shares of the medical instruments supplier’s stock valued at $359,000 after buying an additional 7,247 shares during the last quarter. Creative Planning bought a new position in shares of OraSure Technologies during the 3rd quarter worth $54,000. Finally, Marquette Asset Management LLC bought a new stake in OraSure Technologies in the 3rd quarter valued at about $205,000. 93.50% of the stock is currently owned by institutional investors.

OraSure Technologies Stock Performance

NASDAQ OSUR opened at $3.93 on Tuesday. The company has a market capitalization of $293.14 million, a P/E ratio of 25.87 and a beta of 0.05. OraSure Technologies, Inc. has a 52-week low of $3.72 and a 52-week high of $8.45. The company has a fifty day moving average of $4.14 and a 200-day moving average of $4.34.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $39.92 million for the quarter, compared to analyst estimates of $38.97 million. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The company’s revenue was down 55.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.27 EPS. As a group, analysts forecast that OraSure Technologies, Inc. will post -0.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on OSUR shares. Evercore ISI increased their target price on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a research report on Wednesday, August 7th. StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 4th.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.